focus -WSS

focus

author：entertainment 2025-09-27 23:11:49 - browse：387

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Primary care physicians play key roles in Alzheimer's management

focus

WSS

Primary care physicians play key roles in Alzheimer's management

Oprah kicked off a national conversation on obesity. Let's have it

Eliminate the waiting period for sterilization covered by Medicaid

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Food as medicine: Medically tailored meals may get standardized

Eliminate the waiting period for sterilization covered by Medicaid

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Tori Bowie and the unacceptable rates of Black maternal death

Abortion pill Supreme Court ruling could impact entire drug industry

Medicare details structure of new drug price negotiation program

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Medical leaders decry Supreme Court decision on affirmative action

Free Covid tests will again be offered to all U.S. households

Tori Bowie and the unacceptable rates of Black maternal death

House panel takes first step toward fixing drug shortages

Wikipedia

Information blocking fines are now fair game in health care

'A game

Akili changes sales model for its ADHD video game treatment

Fed up with FDA, ALS advocates consider a take

Eliminate the waiting period for sterilization covered by Medicaid

FDA's naming rule on biosimilars has undermined competition

hotspot

focus

knowledge

knowledge